Can a targeted pill stop breast Cancer's return? new trial hopes to find out
Disease control
Recruiting now
This phase 3 trial tests whether adding the targeted drug abemaciclib to standard hormone therapy can prevent breast cancer from coming back in people with HR-positive, HER2-negative breast cancer who have already had a local recurrence. About 290 participants will receive either…
Phase: PHASE3 • Sponsor: Japanese Foundation for Cancer Research • Aim: Disease control
Last updated Jun 02, 2026 11:59 UTC